Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
Alexis Ogdie, Neilia Kay McGill, Daniel B. Shin, et al.
European Heart Journal (2017) Vol. 39, Iss. 39, pp. 3608-3614
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 280
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi, et al.
The Journal of Rheumatology (2018) Vol. 46, Iss. 1, pp. 7-18
Open Access | Times Cited: 237
Oxidative Stress in Rheumatoid Arthritis: What the Future Might Hold regarding Novel Biomarkers and Add-On Therapies
Lucas José Sá da Fonseca, Valéria Nunes-Souza, Marília Oliveira Fonseca Goulart, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-16
Open Access | Times Cited: 210
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 11, pp. 1400-1413
Open Access | Times Cited: 186
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 7, pp. 1042-1055
Open Access | Times Cited: 165
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn, Julián Panés, Bruce E. Sands, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 50, Iss. 10, pp. 1068-1076
Open Access | Times Cited: 151
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
RMD Open (2020) Vol. 6, Iss. 3, pp. e001395-e001395
Open Access | Times Cited: 144
Diagnosis and Treatment of Lower Extremity Venous Thromboembolism
Romain Chopard, Ida Ehlers Albertsen, Gregory Piazza
JAMA (2020) Vol. 324, Iss. 17, pp. 1765-1765
Closed Access | Times Cited: 142
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 140
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 335-343
Open Access | Times Cited: 116
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Riccardo Pofi, Giorgio Caratti, David Ray, et al.
Endocrine Reviews (2023) Vol. 44, Iss. 6, pp. 975-1011
Closed Access | Times Cited: 70
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott, Samantha Hider, David L. Scott
Drug Safety (2018) Vol. 41, Iss. 7, pp. 645-653
Closed Access | Times Cited: 138
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Joel M. Gelfand, April W. Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology (2021) Vol. 84, Iss. 5, pp. 1254-1268
Open Access | Times Cited: 97
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 169-175
Open Access | Times Cited: 94
Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study
Alexis Ogdie, Sungat K. Grewal, Megan H. Noe, et al.
Journal of Investigative Dermatology (2017) Vol. 138, Iss. 4, pp. 760-767
Open Access | Times Cited: 91
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 189-197
Open Access | Times Cited: 65
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Katie Bechman, Mark Yates, James Galloway
Pharmacological Research (2019) Vol. 147, pp. 104392-104392
Open Access | Times Cited: 74
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
The Lancet Rheumatology (2020) Vol. 2, Iss. 6, pp. e347-e357
Closed Access | Times Cited: 68
C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study
Gro Grimnes, Trond Einar Isaksen, Ynse Ieuwe Gerardus Vladimir Tichelaar, et al.
Haematologica (2018) Vol. 103, Iss. 7, pp. 1245-1250
Open Access | Times Cited: 51
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, et al.
Modern Rheumatology (2019) Vol. 30, Iss. 1, pp. 36-43
Open Access | Times Cited: 50
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
Joel M. Gelfand, April W. Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 6, pp. 1704-1716
Open Access | Times Cited: 49
The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study
Lingyi Li, Na Lu, Ana Michelle Avina-Galindo, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 1, pp. 188-195
Open Access | Times Cited: 45
Risk of venous thromboembolism in rheumatoid arthritis
Chahinez Ketfi, Alexandre Boutigny, Nassim Mohamedi, et al.
Joint Bone Spine (2020) Vol. 88, Iss. 3, pp. 105122-105122
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top